We explored the impact of co-mutation (double or multiple mutation), compared with a single mutation, of the EGFR gene on response to TKIs in a series of patients with metastatic NSCLC.
In the current study, published online in Neuron on 9 December, they report that among a group of 87 patients with major depression, nine carried the mutation, compared with only three people in a control group of 219.
In addition, the Rasgrp1 Anaef mutation could be more similar to the Rasgrp1 null mutation compared with the Rasgrp1 +/- mutation.
Dementia was also significantly more common in probands with the C9ORF72 mutation compared with SOD1 mutation carriers [ 56].
The mortality experience was significantly worse for carriers of a NBS1 mutation, compared with non-carriers (HR=1.85; P=0.008).
Also, the prognosis is worse for those harbouring a truncating PKD1 mutation compared with those with missense mutations [ 8].
Two out of seven (28.5%) familial bilateral cases carried a somatic KIT mutation compared with three out of 116 (2.6%) familial unilateral cases (P=0.026, Fisher's exact test).
In vitro studies revealed a 50% reduction in transactivation ability of the placental promoter harbouring the mutation, compared with wildtype [ 10].
Lower pretreatment Ki67 levels were observed in mutation compared with WT samples (P = 0.051), which was confirmed in an independent data set.
A marginally weaker clinical effect in terms of RR and RFS was also observed in patients with KRAS mutation, compared with those with wild-type KRAS.
